Provided by Tiger Trade Technology Pte. Ltd.

Agenus

7.76
-0.2300-2.88%
Volume:271.00K
Turnover:2.16M
Market Cap:349.36M
PE:3.10
High:8.28
Open:8.09
Low:7.69
Close:7.99
52wk High:8.85
52wk Low:2.71
Shares:45.02M
Float Shares:42.21M
Volume Ratio:1.29
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.50
EPS(LYR):-0.0034
ROE:-1278.83%
ROA:12.53%
PB:-1.75
PE(LYR):-2,285.04

Loading ...

Agenus to present first Phase 2 botensilimab melanoma data at ASCO 2026

Reuters
·
Apr 21

Agenus names BAP Pharma exclusive global partner for botensilimab-balstilimab access programs

Reuters
·
Apr 21

Agenus announces annual shareholder meeting webcast

Reuters
·
Apr 21

Agenus reports Phase 2 results from BOT and BAL with agenT-797

TIPRANKS
·
Apr 18

BRIEF-Agenus Reports Phase Ii Data Demonstrating Immune Reprogramming And Durable Survival With Botensilimab, Balstilimab And Agent-797 In Pd-1 Refractory Gastroesophageal Cancer

Reuters
·
Apr 18

Agenus reports Phase II data showing 77% disease control in PD-1 refractory gastroesophageal cancer

Reuters
·
Apr 18

Agenus Inc - Study Does Not Meet Primary Endpoint of Objective Response Rate

THOMSON REUTERS
·
Apr 18

Agenus to present Phase II BOT+BAL plus agenT-797 data in PD-1 refractory GEC at AACR

Reuters
·
Apr 03

Agenus Announces Data From Phase Ii Study of BOT+Bal in Combination With Agent-797 in Pd-1 Refractory Gastroesophageal Cancer to Be Presented at Aacr 2026

THOMSON REUTERS
·
Apr 03

Agenus Says First Patient Enrolled in Phase 3 Colorectal Cancer Trial

MT Newswires Live
·
Apr 01

Agenus enrolls first patient in Phase 3 BATTMAN trial for BOT+BAL in MSS mCRC

Reuters
·
Apr 01

Agenus Announces First Patient Enrolled in Global Phase 3 Battman Trial of BOT+Bal Immunotherapy Combination in Mss or Pmmr Metastatic Colorectal Cancer

THOMSON REUTERS
·
Apr 01

Agenus: Strengthening Bot/Bal Clinical Profile and Capital-Efficient Path to Registration Underpin Positive Rating

TIPRANKS
·
Apr 01

Agenus to host stakeholder webcast on BOT+BAL immunotherapy program; Q&A to follow live session

Reuters
·
Mar 27

Agenus securities class action dismissed in full; Massachusetts federal court denies leave to amend

Reuters
·
Mar 26

Mink Therapeutics names Melissa Orilall principal financial officer and Austin Charette principal accounting officer

Reuters
·
Mar 20

Agenus (AGEN) Q3 Profit Of US$63.9 Million Tests Longstanding Loss-Making Narrative

Simply Wall St.
·
Mar 18

Agenus to present preliminary BOT+BAL first-line MSS metastatic colorectal cancer data at AACR 2026

Reuters
·
Mar 18

Agenus Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 17

Agenus: Advancing BATTMAN Phase 3 and Leveraging Zydus Partnership to Strengthen Risk‑Reward Profile and Support Buy Rating

TIPRANKS
·
Mar 16